AstraZeneca PLC and Alnylam Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: AstraZeneca vs. Alnylam Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, AstraZeneca PLC and Alnylam Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, consistently spent significantly more, with a peak in 2022 at approximately $19 billion, reflecting its expansive market reach and operational scale. In contrast, Alnylam, a pioneering biotech firm, demonstrated a steady increase in SG&A expenses, growing nearly 18 times from 2014 to 2023, indicating its aggressive growth strategy and market penetration efforts. This comparison highlights the contrasting strategies of a well-established pharmaceutical giant and an innovative biotech challenger, offering insights into their operational priorities and market dynamics. As the industry continues to evolve, these spending patterns provide a window into the strategic directions of these influential companies.